Approximately 10-15 percent of ovarian cancer cases are caused by mutations in the BRCA1 or BRCA2 genes. Women who carry a mutation in either of these genes have a condition called Hereditary Breast and Ovarian Cancer (HBOC) syndrome.1-3 They have an up to 63 percent risk of developing ovarian cancer by age 70.4 In addition, mutation carriers who have already been diagnosed with cancer have a significantly increased risk of developing a second cancer in the future. Patients with Lynch syndrome are also at higher risk of developing ovarian, colon and endometrial cancers. Myriad offers genetic testing that can be used to identify people who carry a BRCA1 or BRCA2 gene mutation or have Lynch syndrome.
In order to assess your risk of carrying a BRCA1, BRCA2 or other gene mutation, your healthcare professional may ask you questions about your personal and family history. Knowing your medical history helps your healthcare professional determine whether you might be an appropriate candidate for genetic testing, which can provide an assessment of your risk of developing ovarian and/or breast cancer, or whether you might have Lynch syndrome.
To help you determine whether you may benefit from hereditary cancer genetic testing, take the Myriad Hereditary Cancer assessment. This assessment can help you get the information you need to discuss your risk of cancer with your healthcare professional.
Take the next step
Knowing your potential risk for HBOC can help you and your healthcare professional make better, more informed decisions about your health, before the onset of cancer or before a second cancer has a chance to develop. Genetic testing for hereditary breast and ovarian cancer with the Myriad Genetics MyRisk™ Hereditary Cancer Test should be considered if:*
If the Myriad MyRisk™ Hereditary Cancer test confirms the presence of a BRCA1 or BRCA2 mutation or a mutation in another gene associated with ovarian cancer risk, the following medical management options may help reduce cancer risk and may either prevent or delay the onset of cancer or detect cancer at an earlier, more treatable stage:†
Using the results of the Myriad MyRisk™ Hereditary Cancer test, your healthcare professional can help you move forward with the right action plan for your particular risk. Your test results can also help your family members learn and understand more about inherited cancer risk and how it may affect them.
*Assessment criteria are based on medical society guidelines.
**HBOC-associated cancers are breast, ovarian, prostate and pancreatic.
†Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
1. Claus EB, et al. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-2324.
2. Pal T, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104(12):2807-2816.
3. Risch H, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001: 68:700-710.
4. Easton DF, et al. Breast and ovarian cancer incidence in BRCA1- mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 56:265-71. PMID: 7825587.
By: Melissa Gonzales - President, Women’s Health, Myriad Genetics
When the big moment comes and parents learn they are having a baby, life changes and anticipation runs high. For many pare...